Research Collaboration and License AgreementCollaboration and License Agreement • May 12th, 2014 • Five Prime Therapeutics Inc • Pharmaceutical preparations • New York
This Research Collaboration and License Agreement (this “Agreement”), effective as of March 14, 2014 (the “Effective Date”), is entered into by and between Bristol-Myers Squibb Company, a Delaware corporation have a place of business at 345 Park Avenue, New York, New York 10154 (“BMS”), and Five Prime Therapeutics, Inc., a Delaware corporation having a place of business at 2 Corporate Drive, South San Francisco, California 94080 (“FivePrime”). BMS and FivePrime are referred to individually as a “Party” and collectively as the “Parties.”
